Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia?

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 5122-5126

  Lee, Shinwon ^a   Choe, Pyoeng Gyun ^a   Song, Kyoung Ho ^a   Park, Sang Won ^a   Kim, Hong Bin ^a   Kim, Nam Joong ^a   Kim, Eui Chong ^a   Park, Wan Beom ^a   Oh, Myoung Don ^a  

^a Seoul National University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; NAFCILLIN; VANCOMYCIN;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOPENIA; DRUG EFFECT; DRUG FEVER; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHICILLIN SUSCEPTIBLE STAPHYLOCOCCUS AUREUS; MORTALITY; PHLEBITIS; PRIORITY JOURNAL; STAPHYLOCOCCAL BACTEREMIA;

ADULT; AGED; BACTEREMIA; CASE-CONTROL STUDIES; CEFAZOLIN; FEMALE; HUMANS; MALE; METHICILLIN; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NAFCILLIN; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 80054704080     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00485-11     Document Type: Article

References (14)

1. Baddour, L. M., et al. 2005. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications. Circulation 111:e394-e434.
2. Bryant, R. E., and R. H. Alford. 1977. Unsuccessful treatment of staphylococcal endocarditis with cefazolin. JAMA 237:569-570. (Pubitemid 8046601)
3. Carrizosa, J., J. Santoro, and D. Kaye. 1978. Treatment of experimental Staphylococcus aureus endocarditis: comparison of cephalothin, cefazolin, and methicillin. Antimicrob. Agents Chemother. 13:74-77. (Pubitemid 8267937)
4. Culver, D. H., et al. 1991. Surgical wound infection rates by wound class, operative procedure, and patient risk index. National Nosocomial Infections Surveillance System. Am. J. Med. 91:152S-157S.
5. Fowler, V. G., Jr., W. M. Scheld, and A. S. Bayer. 2010. Endocarditis and intravascular infections, p. 1067-1112. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Mandell, Douglas, and Bennett's principles and practice of infectious diseases, 7th ed. Churchill Livingstone, Philadelphia, PA.
6. Kim, S. H., et al. 2008. Outcome of vancomycin treatment in patients with methicillin-susceptible Staphylococcus aureus bacteremia. Antimicrob. Agents Chemother. 52:192-197.
7. Miro, J. M., et al. 2005. Staphylococcus aureus native valve infective endocarditis: report of 566 episodes from the International Collaboration on Endocarditis Merged Database. Clin. Infect. Dis. 41:507-514. (Pubitemid 41099645)
8. Mylotte, J. M., and A. Tayara. 2000. Staphylococcus aureus bacteremia: predictors of 30-day mortality in a large cohort. Clin. Infect. Dis. 31:1170-1174. (Pubitemid 32295446)
9. Nannini, E. C., K. V. Singh, and B. E. Murray. 2003. Relapse of type A beta-lactamase-producing Staphylococcus aureus native valve endocarditis during cefazolin therapy: revisiting the issue. Clin. Infect. Dis. 37:1194-1198. (Pubitemid 37372508)
10. Nannini, E. C., et al. 2009. Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus: frequency and possible cause of cefazolin treatment failure. Antimicrob. Agents Chemother. 53:3437-3441.
11. Paul, M., et al. Are all beta-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia? Clin. Microbiol. Infect., in press.
12. Quinn, E. L., et al. 1973. Clinical experiences with cefazolin and other cephalosporins in bacterial endocarditis. J. Infect. Dis. 128:S386-S389.
13. Wynn, M., J. R. Dalovisio, A. D. Tice, and X. Jiang. 2005. Evaluation of the efficacy and safety of outpatient parenteral antimicrobial therapy for infections with methicillin-sensitive Staphylococcus aureus. South. Med. J. 98:590-595. (Pubitemid 40848096)
14. Zygmunt, D. J., C. W. Stratton, and D. S. Kernodle. 1992. Characterization of four beta-lactamases produced by Staphylococcus aureus. Antimicrob. Agents Chemother. 36:440-445.